The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Tarsus Pharmaceuticals Hits Key Milestone as Xdemvy Sales Surpass SG&A Expenses

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Sales of Xdemvy for Demodex blepharitis have exceeded SG&A expenses following an aggressive marketing push.

Tarsus Pharmaceuticals (TARS) has reached a significant financial turning point as sales of its flagship drug, Xdemvy, surpassed its selling, general, and administrative (SG&A) expenses. This achievement follows an aggressive marketing campaign aimed at treating Demodex blepharitis, signaling a clear path toward operational profitability. In a move to strengthen its leadership, the company announced the appointment of David Pyott, former CEO of Allergan, to its Board of Directors. Looking ahead, Tarsus is advancing its clinical pipeline with expectations for major data readouts in the first half of 2027. These catalysts include trials for lotilaner in preventing Lyme disease and treating ocular rosacea. Investors are closely monitoring these developments as the company transitions from a launch-phase biotech to a more established commercial entity.